Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Phase 1 Completed 21 enrolled Stanford University National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.

Timeline

Start: 2004-06
Primary completion: 2012-12
Completion: 2012-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CIK cells	Cell therapy	1e+07 cells/kg	—
Subject	CIK cells	Cell therapy	5e+07 cells/kg	—
Subject	CIK cells	Cell therapy	1e+08 cells/kg	—

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Summary

Timeline

Drugs

Indications